Recommendations for myasthenia gravis clinical trials

Overview of attention for article published in Muscle & Nerve, May 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

policy: 1 policy source

patent: 8 patents

Readers on

mendeley: 102 Mendeley

So far, Altmetric has seen 8 patents that reference this research output.

Methods for treatment of refractory generalized myasthenia gravis

Grant US-12459992-B2

United States of America

04 Nov 2025

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS

Application WO-2023287991-A1

World Intellectual Property Organisation (WIPO)

19 Jan 2023

USE OF COMPLEMENT FACTOR D INHIBITOR FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS

Application WO-2022240612-A1

World Intellectual Property Organisation (WIPO)

17 Nov 2022

USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS

Application WO-2022236047-A1

World Intellectual Property Organisation (WIPO)

10 Nov 2022

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 4 additional patents.